Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment | Journal of the American College of Cardiology
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial - The Lancet
Idarucizumab for dabigatran reversal: the first 6 months in a tertiary centre - Wheeler - 2019 - Internal Medicine Journal - Wiley Online Library
Idarucizumab for Reversal of Dabigatran – Core EM
Idarucizumab dosing in patients with excessive dabigatran body burden - British Journal of Anaesthesia
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects - ScienceDirect
Clinical Evidence | Praxbind® (idarucizumab)
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols - ScienceDirect
Medicina | Free Full-Text | Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials
Medicina | Free Full-Text | Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials
Evidence Supporting Idarucizumab for the Reversal of Dabigatran
Usefulness of initial plasma dabigatran concentration to predict rebound after reversal | Haematologica
Clinical Evidence | Praxbind® (idarucizumab)
Idarucizumab: Plenty of optimism, not enough science - First10EM
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis - MPR
Praxbind Full Prescribing Information, Dosage & Side Effects | MIMS Thailand
Interpretation of idarucizumab clinical trial data based on spontaneous reports of dabigatran adverse effects in the French phar
Idarucizumab for Dabigatran Reversal | NEJM
Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study - Research and Practice in Thrombosis and Haemostasis
FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate) | Business Wire
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis | NEJM
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis | NEJM
